Emmaus Life Sciences Inc (EMMA)

  • Get an in-depth profile of Emmaus Life Sciences Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
0.38 0.00 (0.00%)
Closed USD Disclaimer

Emmaus Life Sciences Inc Company Profile

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
60
Equity Type
ORD
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company that is engaged in the discovery, development, marketing and sale of treatments and therapies for rare and orphan diseases. The Company’s lead product, Endari was approved by the United States Food and Drug Administration (FDA) to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari has received Orphan Drug designation from the FDA and Orphan Medicinal designation from the European Commission. Endari’s safety profile was like the placebo and Endari was well-tolerated in pediatric and adult patients alike. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003 and ELS002. The Company’s subsidiaries include EMI Holding, Inc., Emmaus Medical, Inc., Emmaus Medical Japan, Inc., Newfield Nutrition Corporation, Emmaus Medical Europe Limited, Emmaus Medical Europe Limited and Emmaus Life Sciences, Co. Ltd.
Contact Information
Address
Torrance,90503 United States
Phone
310 214 0065
Fax
310 214 0075
Web
https://www.emmausmedical.com
Top Executives
Name
Age
Since
Title
Willis C. Lee 61 2011 Vice Chairman & COO
Yutaka Niihara 61 2011 Chairman & CEO
Wei Peu Zen 69 2018 Independent Director
Ian Zwicker 75 2022 Independent Director
Seah H. Lim 64 2022 Independent Director

Customize

Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.